Vertex Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Vertex Pharmaceuticals Inc 公司

Vertex Pharmaceuticals Incorporated 是一家全球性生物技術公司。該公司專注於投資科學創新，爲患有嚴重疾病的人創造變革性藥物，重點關注專業市場。該公司擁有四種獲批的治療囊性纖維化 (CF) 潛在病因的藥物，以及一種獲批的治療嚴重鐮狀細胞病 (SCD) 和輸血依賴性β地中海貧血 (TDT) 的療法。其產品線包括 CF、SCD、TDT、急性和神經性疼痛、APOL1 介導的腎臟疾病、1 型糖尿病、1 型肌強直性營養不良和 α-1 抗胰蛋白酶缺乏症的臨牀階段項目。其上市藥物包括 TRIKAFTA/KAFTRIO、SYMDEKO/SYMKEVI（tezacaftor/ivacaftor 和 ivacaftor）、ORKAMBI（lumacaftor/ivacaftor）和 KALYDECO（ivacaftor）。該公司正在開發非自體（同種異體）完全分化、幹細胞衍生的胰島細胞療法，旨在取代 1 型糖尿病患者體內被破壞的產生胰島素的胰島細胞。

公司簡介

公司代碼VRTX

公司名稱Vertex Pharmaceuticals Inc

上市日期Jul 24, 1991

CEODr. Reshma Kewalramani

員工數量6100

證券類型Ordinary Share

年結日Jul 24

公司地址50 Northern Avenue

城市BOSTON

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02210

電話16173416393

網址https://www.vrtx.com/

公司代碼VRTX

上市日期Jul 24, 1991

CEODr. Reshma Kewalramani

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

Mr. Lloyd A. Carney

Independent Director

7.12K

+12.60%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-5.51%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

名稱

名稱/職務

職務

持股

持股變動

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

TRIKAFTA

2.54B

91.86%

Other product revenues

156.60M

5.67%

ALYFTREK

53.90M

1.95%

CASGEVY

14.20M

0.51%

地區USD

名稱

營收

佔比

United States

1.65B

59.91%

Europe

826.60M

29.95%

Other

280.10M

10.15%

業務

地區

業務USD

名稱

營收

佔比

TRIKAFTA

2.54B

91.86%

Other product revenues

156.60M

5.67%

ALYFTREK

53.90M

1.95%

CASGEVY

14.20M

0.51%

股東統計

更新時間: 8月17日週日

持股股東

股東類型

持股股東

佔比

Capital World Investors

11.21%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

6.28%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Global Advisors (US)

4.59%

其他

63.09%

持股股東

佔比

Capital World Investors

11.21%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

6.28%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Global Advisors (US)

4.59%

其他

63.09%

股東類型

持股股東

佔比

Investment Advisor

60.29%

Investment Advisor/Hedge Fund

28.71%

Research Firm

2.55%

Pension Fund

2.27%

Bank and Trust

1.99%

Sovereign Wealth Fund

1.49%

Hedge Fund

0.69%

Individual Investor

0.14%

Insurance Company

0.09%

其他

1.76%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

2023Q1

2468

250.11M

97.13%

-4.74M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

28.53M

11.11%

+207.61K

+0.73%

Mar 31, 2025

The Vanguard Group, Inc.

23.38M

9.1%

+232.41K

+1.00%

Mar 31, 2025

Capital Research Global Investors

14.54M

5.66%

+4.11M

+39.38%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

14.00M

5.45%

-330.35K

-2.31%

Mar 31, 2025

State Street Global Advisors (US)

11.79M

4.59%

-190.75K

-1.59%

Mar 31, 2025

Fidelity Management & Research Company LLC

7.62M

2.97%

-1.49M

-16.32%

Mar 31, 2025

Jennison Associates LLC

5.06M

1.97%

+744.68K

+17.25%

Mar 31, 2025

Geode Capital Management, L.L.C.

5.76M

2.24%

+113.52K

+2.01%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

5.31M

2.07%

-20.76K

-0.39%

Jun 30, 2025

Wellington Management Company, LLP

5.45M

2.12%

-461.34K

-7.80%

Mar 31, 2025

持股ETF

更新時間: 9月2日週二

機構名稱

佔比

VanEck Biotech ETF

10.62%

iShares Biotechnology ETF

6.92%

First Trust NYSE Arca Biotechnology Index Fund

3.35%

SPDR S&P Biotech ETF

2.44%

iShares U.S. Healthcare ETF

2.39%

Health Care Select Sector SPDR Fund

2.34%

Fidelity MSCI Health Care Index ETF

2.06%

First Trust NASDAQ-100 Ex-Technology Sector Index Fund

1.81%

Capital Group Core Equity ETF

1.77%

iShares Global Healthcare ETF

1.68%

VanEck Biotech ETF

佔比10.62%

iShares Biotechnology ETF

佔比6.92%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.35%

SPDR S&P Biotech ETF

佔比2.44%

iShares U.S. Healthcare ETF

佔比2.39%

Health Care Select Sector SPDR Fund

佔比2.34%

Fidelity MSCI Health Care Index ETF

佔比2.06%

First Trust NASDAQ-100 Ex-Technology Sector Index Fund

佔比1.81%

Capital Group Core Equity ETF

佔比1.77%

iShares Global Healthcare ETF

佔比1.68%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Vertex Pharmaceuticals Inc

387.150USD

Vertex Pharmaceuticals Inc

387.150

概覽

公司

財務

分析